Partnership to advance the application of microscopy in drug discovery Labmate Online
In a combined effort to improve the early development of complex drugs, the Medicines Discovery Catapult (MDC) and Zeiss have joined forces to integrate advanced microscopy techniques into the early stages of the drug discovery process to assess the potency drugs in disease models.
With specialist microscopy capabilities already established at its Alderley Park-based laboratory facilities, MDC will apply its cell biology and drug discovery expertise with ZEISS microscope instrumentation and image analysis capabilities to pilot advanced microscopy workflows (e.g. confocal, lightsheet, multiphoton and super-resolution microscopy) to measure the interaction between drug molecules and biological systems and develop assays specifically suited for drug discovery.
Assessing cellular internalization, to ensure that a lead molecule can enter the cell and provide an effective response, is a critical step in this process. As part of the project, MDC and ZEISS will produce a live cell imaging and image analysis pipeline that can be deployed to evaluate new drug delivery technologies and therapies, enabling innovators to advance their research.
Michael Albiez, Head of ZEISS Research Microscopy Solutions, said, “We are thrilled to partner with MDC to pursue our shared goal of enabling drug hunters around the world to discover and develop better drugs faster. Combining MDC’s expertise in drug discovery with our unique capabilities in imaging modalities, workflow automation and AI-powered image analysis will undoubtedly pave the way for new powerful new discoveries in the biopharmaceutical field.
Dr. Martin Main, Chief Scientist at the MDC, said: “Advanced microscopy offers a range of benefits to drug discovery, from characterizing complex cellular models of disease to understanding the molecular mechanism of action medication. MDC’s advanced microscopy capability enables UK drug discovery innovators to access this essential R&D resource to advance their goals more effectively and efficiently, bringing better treatments to patients, faster.
“Through this partnership, we will push the boundaries of advanced microscopy in drug discovery, driving the adoption of new scientific tools and techniques for drug discovery,” he added.
MDC’s aim is to reshape the UK’s drug discovery industry, turning great UK science into better treatments through partnership. He works to address challenges posed by industry, overcome barriers that limit today’s drug discovery through effective interventions, and industrialize new technologies to drive the adoption of new tools and techniques. drug discovery scientists.
More information on line